Literature DB >> 8185615

Soluble amyloid beta-protein is a marker of Alzheimer amyloid in brain but not in cerebrospinal fluid.

M Tabaton1, M G Nunzi, R Xue, M Usiak, L Autilio-Gambetti, P Gambetti.   

Abstract

The amyloid beta protein (A beta), a 4 kD fragment of the beta amyloid precursor protein, is deposited as insoluble amyloid in the brain of Alzheimer disease (AD) subjects. Soluble A beta is a normal metabolic product and is present in cerebrospinal fluid. We identified soluble A beta forms of 4kD, 3kD and 3.7kD in AD but not in control brains free of amyloid deposits. All three forms of soluble A beta extend beyond residue 40. Analysis of cerebrospinal fluid from the same subjects confirmed the presence of only 4kD A beta in comparable amounts in AD and controls. The presence of soluble A beta only in brain regions with amyloid suggests they are related. The undetectability of soluble A beta in control brains indicates that it is normally removed or bound to other proteins. Failure of this protective mechanism might cause amyloid formation in AD.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8185615     DOI: 10.1006/bbrc.1994.1634

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  27 in total

Review 1.  Cerebrospinal fluid protein biomarkers for Alzheimer's disease.

Authors:  Kaj Blennow
Journal:  NeuroRx       Date:  2004-04

2.  Cerebral amyloid angiopathy: amyloid beta accumulates in putative interstitial fluid drainage pathways in Alzheimer's disease.

Authors:  R O Weller; A Massey; T A Newman; M Hutchings; Y M Kuo; A E Roher
Journal:  Am J Pathol       Date:  1998-09       Impact factor: 4.307

3.  Opposite roles of apolipoprotein E in normal brains and in Alzheimer's disease.

Authors:  C Russo; G Angelini; D Dapino; A Piccini; G Piombo; G Schettini; S Chen; J K Teller; D Zaccheo; P Gambetti; M Tabaton
Journal:  Proc Natl Acad Sci U S A       Date:  1998-12-22       Impact factor: 11.205

4.  The levels of water-soluble and triton-soluble Aβ are increased in Alzheimer's disease brain.

Authors:  Jessica M McDonald; Nigel J Cairns; Lisa Taylor-Reinwald; David Holtzman; Dominic M Walsh
Journal:  Brain Res       Date:  2012-02-24       Impact factor: 3.252

5.  Alzheimer's disease amyloid beta-protein forms Zn(2+)-sensitive, cation-selective channels across excised membrane patches from hypothalamic neurons.

Authors:  M Kawahara; N Arispe; Y Kuroda; E Rojas
Journal:  Biophys J       Date:  1997-07       Impact factor: 4.033

Review 6.  APP/Aβ structural diversity and Alzheimer's disease pathogenesis.

Authors:  Alex E Roher; Tyler A Kokjohn; Steven G Clarke; Michael R Sierks; Chera L Maarouf; Geidy E Serrano; Marwan S Sabbagh; Thomas G Beach
Journal:  Neurochem Int       Date:  2017-08-12       Impact factor: 3.921

7.  Effects of the amyloid precursor protein Glu693-->Gln 'Dutch' mutation on the production and stability of amyloid beta-protein.

Authors:  D J Watson; D J Selkoe; D B Teplow
Journal:  Biochem J       Date:  1999-06-15       Impact factor: 3.857

8.  Human blood-brain barrier receptors for Alzheimer's amyloid-beta 1- 40. Asymmetrical binding, endocytosis, and transcytosis at the apical side of brain microvascular endothelial cell monolayer.

Authors:  J B Mackic; M Stins; J G McComb; M Calero; J Ghiso; K S Kim; S D Yan; D Stern; A M Schmidt; B Frangione; B V Zlokovic
Journal:  J Clin Invest       Date:  1998-08-15       Impact factor: 14.808

9.  Predominant deposition of amyloid-beta 42(43) in plaques in cases of Alzheimer's disease and hereditary cerebral hemorrhage associated with mutations in the amyloid precursor protein gene.

Authors:  D M Mann; T Iwatsubo; Y Ihara; N J Cairns; P L Lantos; N Bogdanovic; L Lannfelt; B Winblad; M L Maat-Schieman; M N Rossor
Journal:  Am J Pathol       Date:  1996-04       Impact factor: 4.307

10.  A facile method for expression and purification of the Alzheimer's disease-associated amyloid beta-peptide.

Authors:  Dominic M Walsh; Eva Thulin; Aedín M Minogue; Niklas Gustavsson; Eric Pang; David B Teplow; Sara Linse
Journal:  FEBS J       Date:  2009-03       Impact factor: 5.542

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.